{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:36:10Z","timestamp":1778056570995,"version":"3.51.4"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:sec id=\"ab-ioi240098-4\"><jats:title>Importance<\/jats:title><jats:p>People living with HIV and atrial fibrillation (AF) often receive anticoagulation that may interact with their antiretroviral therapy (ART). No studies exist comparing the safety of oral anticoagulants in this population.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ioi240098-5\"><jats:title>Objective<\/jats:title><jats:p>To compare the bleeding risks among warfarin, rivaroxaban, and apixaban users in a national US cohort with AF and HIV.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ioi240098-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>A new-user, active-comparator, propensity score overlap-weighted cohort study using the target trial emulation framework including Medicare claims database data (January 1, 2013, to December 31, 2020) was carried out. The analysis was conducted from July 2023 to April 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ioi240098-7\"><jats:title>Exposure<\/jats:title><jats:p>New initiators of warfarin vs apixaban, rivaroxaban vs apixaban, and rivaroxaban vs warfarin aged 50 years or older with nonvalvular AF and HIV.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ioi240098-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was hospitalization for major bleeding. Secondary outcomes included hospitalization for gastrointestinal bleeding, ischemic stroke, and all-cause mortality.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ioi240098-9\"><jats:title>Results<\/jats:title><jats:p>Overall, 2683 individuals (mean [SD] age, 66.22 [8.97] years; 580 female individuals [21.6%]) in the warfarin vs apixaban cohort, 2176 (mean [SD] age, 66.61 [8.87] years; 455 female individuals [20.9%]) in the rivaroxaban vs apixaban cohort, and 1787 (mean age, 65.47 years; 377 female individuals [21.1%]) in the rivaroxaban vs warfarin cohort. After propensity score overlap weighting, warfarin initiation was associated with a higher rate of major bleeding than initiation of apixaban (hazard ratio [HR], 2.60; 95% CI, 1.51-4.49), including major gastrointestinal bleeding (HR, 2.99; 95% CI, 1.52-5.90). This association was intensified in the 71% of patients taking concurrent ART (major bleeding, HR, 6.68; 95% CI, 2.78-16.02; gastrointestinal bleeding, HR, 5.28; 95% CI, 2.08-13.42). Rivaroxaban vs apixaban was also associated with a higher rate of major bleeding (HR, 2.15; 95% CI, 1.18-3.94) and gastrointestinal bleeding (HR, 3.38; 95% CI, 1.57-7.25), with a stronger association in those using ART (major bleeding, HR, 4.83; 95% CI, 2.11-11.08; gastrointestinal bleeding, HR, 4.76; 95% CI, 1.78-12.70). Estimates were similar when comparing rivaroxaban with warfarin. No significant difference was observed in the rate of ischemic stroke or mortality among the 3 oral anticoagulants.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ioi240098-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This study found that in patients with HIV and AF, especially those treated with ART, warfarin and rivaroxaban were associated with higher rates of major bleeding compared with apixaban, suggesting a superior safety profile for apixaban in this high-risk population.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamainternmed.2024.8335","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T16:35:17Z","timestamp":1740414917000},"page":"431","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral Anticoagulants"],"prefix":"10.1001","volume":"185","author":[{"given":"Claire M.","family":"Quinlan","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Avorn","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Singer","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Cervone","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kueiyu Joshua","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"9635","key":"ioi240098r1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.","volume":"372","author":"Antiretroviral Therapy Cohort Collaboration","year":"2008","journal-title":"Lancet"},{"key":"ioi240098r2","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1097\/QAD.0000000000001401","article-title":"The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development.","volume":"31","author":"Smith","year":"2017","journal-title":"AIDS"},{"issue":"Suppl 2","key":"ioi240098r3","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1097\/QAD.0000000000001444","article-title":"Geriatric syndromes: new frontiers in HIV and sarcopenia.","volume":"31","author":"Hawkins","year":"2017","journal-title":"AIDS"},{"issue":"2","key":"ioi240098r4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/157340309788166705","article-title":"Heart disease in patients with HIV\/AIDS-an emerging clinical problem.","volume":"5","author":"Gopal","year":"2009","journal-title":"Curr Cardiol Rev"},{"issue":"22","key":"ioi240098r5","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.jacc.2013.03.022","article-title":"Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity.","volume":"61","author":"Hsu","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ioi240098r6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21556660.2022.2149963","article-title":"Treatment and comorbidity burden among people living with HIV: a review of systematic literature reviews.","volume":"12","author":"Taiwo","year":"2022","journal-title":"J Drug Assess"},{"issue":"6","key":"ioi240098r7","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/COH.0000000000000412","article-title":"Use of direct oral anticoagulants for treatment of atrial fibrillation in patients with HIV: a review.","volume":"12","author":"West","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"ioi240098r8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/QAI.0b013e31825c7f24","article-title":"Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system.","volume":"60","author":"Chow","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"19","key":"ioi240098r9","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1212\/WNL.0000000000001560","article-title":"HIV status and the risk of ischemic stroke among men.","volume":"84","author":"Sico","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"ioi240098r10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/COH.0000000000000701","article-title":"The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy.","volume":"16","author":"Nhean","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"ioi240098r11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02275-17","article-title":"Ritonavir-boosted protease inhibitors but not cobicistat appear safe in HIV-positive patients ingesting dabigatran.","volume":"62","author":"Kakadiya","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"ioi240098r12","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults.","volume":"71","author":"By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"ioi240098r13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4212\/cjhp.v66i2.1235","article-title":"Venous thromboembolism due to suspected interaction between rivaroxaban and nevirapine.","volume":"66","author":"Bates","year":"2013","journal-title":"Can J Hosp Pharm"},{"issue":"2","key":"ioi240098r15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1517\/14740330903493458","article-title":"Drug interactions with antiretrovirals and warfarin.","volume":"9","author":"Liedtke","year":"2010","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"ioi240098r16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/QAI.0000000000001470","article-title":"CHA2DS2-VASc score, warfarin use, and risk for thromboembolic events among HIV-infected persons with atrial fibrillation.","volume":"76","author":"Chau","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"ioi240098r18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/QAI.0000000000001653","article-title":"Burden of exposure to potential interactions between antiretroviral and non-antiretroviral medications in a population of HIV-positive patients aged 50 years or older.","volume":"78","author":"Ranzani","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"ioi240098r19","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1177\/1060028013504075","article-title":"Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients.","volume":"47","author":"Tseng","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"3","key":"ioi240098r20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.","volume":"76","author":"Mueck","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"ioi240098r21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.2452","article-title":"Roadmap to 2030 for drug evaluation in older adults.","volume":"112","author":"Liu","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"ioi240098r22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/1060028014523115","article-title":"Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications.","volume":"48","author":"Egan","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"11","key":"ioi240098r23","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40262-015-0290-2","article-title":"Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update.","volume":"54","author":"Teng","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"ioi240098r24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/aid.2019.0098","article-title":"HIV care among elderly population: systematic review and meta-analysis.","volume":"36","author":"Bhatta","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"11","key":"ioi240098r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020.","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"ioi240098r26","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1097\/01.mlr.0000223670.00890.74","article-title":"Development and verification of a \u201cvirtual\u201d cohort using the National VA Health Information System.","volume":"44","author":"Fultz","year":"2006","journal-title":"Med Care"},{"issue":"10","key":"ioi240098r27","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1161\/01.STR.0000032240.28636.BD","article-title":"Validating administrative data in stroke research.","volume":"33","author":"Tirschwell","year":"2002","journal-title":"Stroke"},{"issue":"1","key":"ioi240098r28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/pds.1518","article-title":"Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data.","volume":"17","author":"Roumie","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"ioi240098r29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use.","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"ioi240098r30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"12","key":"ioi240098r31","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"issue":"5","key":"ioi240098r32","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"6","key":"ioi240098r33","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/gerona\/glz224","article-title":"Measuring frailty in administrative claims data: comparative performance of four claims-based frailty measures in the U.S. Medicare data.","volume":"75","author":"Kim","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"ioi240098r34","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index.","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"8","key":"ioi240098r35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/gerona\/gly197","article-title":"Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study.","volume":"74","author":"Kim","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"ioi240098r36","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/gerona\/glaa150","article-title":"Updating International Classification of Diseases 9th Revision to 10th Revision of a claims-based frailty index.","volume":"76","author":"Gautam","year":"2021","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"ioi240098r37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores.","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"ioi240098r38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006814","article-title":"Prediction score for anticoagulation control quality among older adults.","volume":"6","author":"Lin","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"23","key":"ioi240098r39","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial.","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"ioi240098r41","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00009-X","article-title":"Long-acting injectable ART for HIV: a (cautious) step forward.","volume":"3","author":"Venkatesan","year":"2022","journal-title":"Lancet Microbe"},{"issue":"3","key":"ioi240098r42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1055\/a-1508-8187","article-title":"Using a simple prescription gap to determine warfarin discontinuation can lead to substantial misclassification.","volume":"122","author":"Lin","year":"2022","journal-title":"Thromb Haemost"},{"issue":"7","key":"ioi240098r43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.7326\/M19-2522","article-title":"Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study.","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"issue":"5","key":"ioi240098r44","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1136\/heartjnl-2020-318753","article-title":"Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation.","volume":"108","author":"Rutherford","year":"2022","journal-title":"Heart"},{"issue":"3","key":"ioi240098r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4086","article-title":"Comparative effectiveness and safety of oral anticoagulants by dementia status in older patients with atrial fibrillation.","volume":"6","author":"Lin","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"ioi240098r46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1053\/j.ajkd.2023.08.017","article-title":"Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide US cohort study.","volume":"83","author":"Fu","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"ioi240098r47","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1089\/apc.2012.0068","article-title":"Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals.","volume":"26","author":"Anderson","year":"2012","journal-title":"AIDS Patient Care STDS"},{"issue":"5","key":"ioi240098r48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cjco.2019.06.002","article-title":"Stroke and systemic thromboembolism prevention in people living with human immunodeficiency virus with atrial fibrillation: a review of its implications for clinical practice.","volume":"1","author":"Vizcarra","year":"2019","journal-title":"CJC Open"},{"issue":"4","key":"ioi240098r49","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/09540121.2016.1257774","article-title":"Adherence to combination antiretroviral treatment and clinical outcomes in a Medicaid sample of older HIV-infected adults.","volume":"29","author":"Abara","year":"2017","journal-title":"AIDS Care"},{"key":"ioi240098r14","unstructured":"Oral Anticoagulant | Rx ELIQUIS (apixaban) Safety Info. Accessed July 24, 2023. https:\/\/www.eliquis.com\/eliquis\/hcp"},{"key":"ioi240098r17","unstructured":"HIV and the Older Person | NIH. Accessed February 10, 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/hiv-and-older-person"},{"key":"ioi240098r40","unstructured":"Aetion. Aetion Evidence Platform (2023). Accessed January 27, 2025. https:\/\/aetion.com"},{"key":"ioi240098r50","unstructured":"US Centers for Disease Control and Prevention. 2021 HIV incidence. Accessed February 19, 2024. https:\/\/www.cdc.gov\/nchhstp\/newsroom\/releases\/2023\/2021-hiv-incidence.html#:~:text=Estimated%20annual%20new%20HIV%20infections,among%20gay%20and%20bisexual%20males"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2830181\/jamainternal_quinlan_2025_oi_240098_1743791961.12179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T19:34:07Z","timestamp":1744054447000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2830181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2024.8335","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}